Literature DB >> 8961366

Limited field irradiation in early stage (T1-2N0) non-small cell lung cancer.

B J Slotman1, I E Antonisse, K H Njo.   

Abstract

BACKGROUND AND
PURPOSE: Radiotherapy can effectively control non-small cell lung cancers (NSCLC) of limited size. This study is conducted to investigate whether limited field irradiation, without irradiation of regional lymph nodes, can safely be used in these patients.
MATERIALS AND METHODS: Between 1988 and 1993, 31 patients with operable T1-2N0 NSCLC received radiotherapy (48 Gy in 12 fractions) to a limited ('postage stamp') field. The hilum and mediastinum were not included in the radiation portals.
RESULTS: Overall survival was 42% at 3 years. Disease-specific survival at 3 years was 76%. One patient developed an isolated regional failure, one had a combined local and distant failure, one had a combined local, regional and distant failure, while three patients failed at distant sites only. Thus, only two patients (6%) recurred regionally.
CONCLUSIONS: This study shows that 'postage stamp' irradiation is an effective alternative to surgery. Radiation of the hilar and mediastinal lymph nodes can be omitted in these pulmonary compromised patients.

Entities:  

Mesh:

Year:  1996        PMID: 8961366     DOI: 10.1016/s0167-8140(96)91827-7

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  9 in total

Review 1.  21 years of biologically effective dose.

Authors:  J F Fowler
Journal:  Br J Radiol       Date:  2010-07       Impact factor: 3.039

2.  Additional data in the debate on stage I non-small cell lung cancer: surgery versus stereotactic ablative radiotherapy.

Authors:  Charles B Simone; Jay F Dorsey
Journal:  Ann Transl Med       Date:  2015-08

3.  Effect of histologic type on recurrence pattern in radiation therapy for medically inoperable patients with stage I non-small-cell lung cancer.

Authors:  Hitoshi Ishikawa; Yuko Nakayama; Yoshizumi Kitamoto; Tetsuo Nonaka; Hidemasa Kawamura; Katsuyuki Shirai; Hideyuki Sakurai; Kazushige Hayakawa; Hideo Niibe; Takashi Nakano
Journal:  Lung       Date:  2006-11-03       Impact factor: 2.584

Review 4.  Are three doses of stereotactic ablative radiotherapy (SABR) more effective than 30 doses of conventional radiotherapy?

Authors:  Anna O Simeonova; Katharina Fleckenstein; Hansjörg Wertz; Anian Frauenfeld; Judit Boda-Heggemann; Frank Lohr; Frederik Wenz
Journal:  Transl Lung Cancer Res       Date:  2012-03

Review 5.  Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review.

Authors:  N P Rowell; C J Williams
Journal:  Thorax       Date:  2001-08       Impact factor: 9.139

6.  Outcomes of accelerated hypofractionated radiotherapy in stage i non-small-cell lung cancer.

Authors:  T Yung; M E Giuliani; L W Le; A Sun; B C J Cho; A Bezjak; A Brade; A J Hope
Journal:  Curr Oncol       Date:  2012-08       Impact factor: 3.677

7.  Initial clinical experience with stereotactic lung radiotherapy, based on a biological model-driven prescription method.

Authors:  C Wesley Hodge; Wolfgang A Tomé; Tracy Weigel; Anne M Traynor; Minesh P Mehta
Journal:  J Radiosurg SBRT       Date:  2011

8.  Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases.

Authors:  Peter Fritz; Hans-Jörg Kraus; Werner Mühlnickel; Udo Hammer; Wolfram Dölken; Walburga Engel-Riedel; Assad Chemaissani; Erich Stoelben
Journal:  Radiat Oncol       Date:  2006-08-20       Impact factor: 3.481

9.  Preliminary study of percutaneous alcohol injection into the lung.

Authors:  K Suzuki; N Moriyama; T Yokose; Y Nakaya; T Ishihara; S Niho; K Nagai; H Esumi
Journal:  Jpn J Cancer Res       Date:  1998-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.